The phase III AFFINITY study failed to show a statistically significant improvement in overall survival for patients treated with custirsen in combination with cabazitaxel/prednisone compared to cabazitaxel/prednisone alone.
Eli Lilly and Co. said that following a pre-planned interim analysis of the MONARCH 2 trial, an independent data monitoring committee provided the recommendation to continue the study without modification as the interim efficacy criteria were not met.
Takeda Pharmaceutical Co. Ltd. and Seattle Genetics Inc. said that the phase III ALCANZA clinical trial evaluating Adcetris (brentuximab vedotin) in cutaneous T-cell lymphoma met its primary endpoint, demonstrating a highly statistically significant improvement in the rate of objective response lasting at least four months (ORR4).
Genentech announced positive results for Tecentriq (atezolizumab) from the Phase III study OAK. The study met its co-primary endpoints and showed a statistically significant and clinically meaningful improvement in overall survival compared with docetaxel chemotherapy in people with locally advanced or metastatic non-small cell lung cancer whose disease progressed on or after treatment with platinum-based chemotherapy.
BRIAN GOLDSTEIN was named chief health system officer of UW Medicine and vice president for medical affairs at the University of Washington. He is the executive vice president and chief operating officer for the University of North Carolina Hospitals. Goldstein will be responsible for overseeing the operations of the clinical entities of UW Medicine and... […]
THE NATIONAL COMPREHENSIVE CANCER NETWORK is extending its collaboration with New Century Health to integrate the NCCN Imaging Appropriate Use Criteria into New Century Health’s value-based clinical decision support platform. This will provide expanded access to imaging recommendations as derived from the NCCN Clinical Practice Guidelines in Oncology. New Century Health has been a licensee... […]
THE NCI TRANSLATIONAL RESEARCH PROGRAM published the full list of FY2016 Specialized Programs of Research Excellence grantees. The SPORE program uses the P50 grant funding mechanism to promote collaborative, interdisciplinary, translational cancer multi-project research. SPOREs are primarily focused on organ site disease, but also on themes that cut across organ sites. Including the 2016 grantees,... […]
WILLIAM KAELIN, Peter Ratcliffe, and Gregg Semenza received the 2016 Lasker Award for basic medical research. Ralf Bartenschlager, Charles Rice, and Michael Sofia received the award for clinical research, and Bruce Alberts for special achievement. The awards, which carry an honorarium of $250,000 for each category, will be presented on Friday, Sept. 23, in New... […]
ERIC FEARON was named director of the University of Michigan Comprehensive Cancer Center.
THE EUROPEAN COMMISSION issued a marketing authorization for lenvatinib (Kisplyx) in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF)-targeted therapy. Lenvatinib was granted an accelerated assessment by the European Medicines Agency in October 2015. Marketing authorization follows the evaluation of results... […]
